David Dai
Stock Analyst at UBS
(0.54)
# 3,986
Out of 4,944 analysts
24
Total ratings
22.73%
Success rate
-23.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $13.45 | +160.22% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $10.57 | +145.98% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $26.87 | +11.65% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.45 | -18.37% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.64 | +214.14% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $78.24 | +27.81% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.49 | +115.72% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $33.00 | -27.27% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.81 | +424.93% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $67.22 | +7.11% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $24.91 | +177.00% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.42 | +104.75% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $26.49 | +126.50% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.69 | +3,981.63% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $23.21 | +72.34% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.66 | +2,309.64% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.21 | +2,162.44% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $32.51 | +59.95% | 1 | Mar 17, 2020 |
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $13.45
Upside: +160.22%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $10.57
Upside: +145.98%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $26.87
Upside: +11.65%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.45
Upside: -18.37%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.64
Upside: +214.14%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $78.24
Upside: +27.81%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.49
Upside: +115.72%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $33.00
Upside: -27.27%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.81
Upside: +424.93%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $67.22
Upside: +7.11%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $24.91
Upside: +177.00%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $24.42
Upside: +104.75%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $26.49
Upside: +126.50%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.69
Upside: +3,981.63%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $23.21
Upside: +72.34%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.66
Upside: +2,309.64%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.21
Upside: +2,162.44%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $32.51
Upside: +59.95%